Our BusinessCompany ProfileEli Lilly and Company is a leading innovation-driven pharmaceutical corporation committed to developing a growing portfolio of best-in-class pharmaceutical products that help people live longer, healthier, and more active lives. We have a long history of meaningful medical innovation, most notably in the treatment of infections, diabetes, and depression. A timeline illustrates some significant events in the history of our development as a responsible public corporation. The Lilly Difference/Our Company
In 2005, more than 42,600 people worked for Lilly worldwide. Lilly has sales offices in 89 countries and we market our products in approximately 143 countries. Lilly has been a publicly held company for more than 50 years. Eli Lilly and Company common stock is listed on the U.S. New York and Pacific stock exchanges and the London and Swiss stock exchanges. On the New York Stock Exchange, our shares trade under the ticker symbol LLY. Lilly Manufacturing
In 2005, our global manufacturing operations consisted of 25 sites. More than 12,500 manufacturing employees work at sites in Brazil, China, Egypt, France, Germany, Ireland, Italy, Japan, Mexico, Puerto Rico, Spain, the United Kingdom, and the United States. Skilled in the art of making medicine, these employees make and supply products sold in 143 countries. Lilly manufacturing consists of complex operations where employees translate deep knowledge of science, chemistry, engineering, production, and numerous other disciplines into the reliable manufacture and supply of high-quality, safe, and effective medicines. Because of the unique challenges associated with making medicine, we place special emphasis on ensuring that our operations are safe in the broadest sense of the word—for patients, employees, the environment, and the communities in which we operate. This means that the health, safety, environmental, and quality aspects of making medicine are the starting point for all that we do. In 2005, Lilly reached a milestone in its efforts to improve quality in manufacturing, with a successful inspection by the U.S. Food and Drug Administration at Lilly Technology Center. Lilly is fully committed to ensuring compliance with current good manufacturing practices as required by all regulatory agencies that govern our industry. In addition, we are driving a renewed cultural mindset where compliance is the minimum expectation and continuous improvement is a primary objective at every site, every day. The success of these efforts has led to operational improvements that are having an important and lasting impact on the company’s overall success. Lilly Research and Development Research and development locations in the United States include two sites in Indiana (Indianapolis and Greenfield). During 2005, we relocated our LRL development operations from West Lafayette to Indianapolis. We also closed our research operations located in Lilly’s Research Triangle Park Laboratories in North Carolina and relocated the operations to our Indianapolis facility. Outside the U.S., our research and development facilities are located in Australia*, Belgium, Canada, China*, England, Germany, Japan, Singapore, and Spain. Lilly conducts clinical research in more than 50 countries. Elanco Animal Health A division of Lilly, Elanco Animal Health markets products worldwide to improve the health of animals. Products are marketed primarily to cattle, poultry, and swine producers. With key operations in North America, Europe, the Middle East, Africa, the Asia-Pacific area, and Latin America, Elanco employs about 2,000 people and markets its products in more than 100 countries. Corporate Financial InformationOur worldwide sales for 2005 were $14.6 billion. More detailed information on Lilly’s financial performance is provided in our 2005 Annual Report.
Chairman's Letter |
||||||||||||||||||||||||||||||||||||||||||||
Products|
R&D|
News|
About|
Careers|
Investors
Highlights